Nederlands (Nederland)
OKEDI®
risperidon, powder and solvent for prolonged-release suspension for injectionRecent introduction
Until recently, there was no distributor in the Netherlands, which mean that OKEDI® was only available to a limited extent through parallel imports, resulting in insufficient availability. The manufacturer has now appointed Fagron as its distributor. The product is sufficiently available and can only be ordered directly from Fagron by (hospital) pharmacies and not from regular wholesalers.See the SmPC and patient information leaflet on the EMA website for more information about this product.
SmPC and patient information leaflet
Scientific background information
PRISMA-3 study short term
PRISMA-3 study long term
BORIS study
Pharmacokinetics
EPAR European public assessment report
Availability and further information?
Until recently, there was no distributor in the Netherlands, which mean that OKEDI® was only available to a limited extent through parallel imports, resulting in insufficient availability. The manufacturer has now appointed Fagron as its distributor. The product is now available and can be ordered from Fagron.Would you like to know more about using OKEDI® for your new or existing patients? Or would you like to get in touch with a Fagron representative? Please do not hesitate to contact us at innovation@fagron.nl or fill in the form.Â
Our pharmacists are ready to help you.
1. OKEDI® SmPC (februari 2022) 2. Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, Torres F, MartÃnez J. Efficacy and safety of once-monthly Risperidone ISM®  in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020 Nov 25;6 (1):37. 3. Walling DP, Hassman HA, Anta L, Ochoa L, Ayani I, MartÃnez J, Gutierro I. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Drug Des Devel Ther. 2021 Oct 15;15:4371-4382. 4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 Apr;157(4):514-520. 5. Filts Y, Litman RE, MartÃnez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. SchizophrRes. 2022 Jan;239:83-91.
Recent introduction
Until recently, there was no distributor in the Netherlands, which mean that OKEDI® was only available to a limited extent through parallel imports, resulting in insufficient availability. The manufacturer has now appointed Fagron as its distributor. The product is sufficiently available and can only be ordered directly from Fagron by (hospital) pharmacies and not from regular wholesalers.See the SmPC and patient information leaflet on the EMA website for more information about this product.
Scientific background information
Availability and further information?
Until recently, there was no distributor in the Netherlands, which mean that OKEDI® was only available to a limited extent through parallel imports, resulting in insufficient availability. The manufacturer has now appointed Fagron as its distributor. The product is now available and can be ordered from Fagron.Would you like to know more about using OKEDI® for your new or existing patients? Or would you like to get in touch with a Fagron representative? Please do not hesitate to contact us at innovation@fagron.nl or fill in the form.Â
Our pharmacists are ready to help you.
1. OKEDI® SmPC (februari 2022) 2. Correll CU, Litman RE, Filts Y, Llaudó J, Naber D, Torres F, MartÃnez J. Efficacy and safety of once-monthly Risperidone ISM®  in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020 Nov 25;6 (1):37. 3. Walling DP, Hassman HA, Anta L, Ochoa L, Ayani I, MartÃnez J, Gutierro I. The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study. Drug Des Devel Ther. 2021 Oct 15;15:4371-4382. 4. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 Apr;157(4):514-520. 5. Filts Y, Litman RE, MartÃnez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study. SchizophrRes. 2022 Jan;239:83-91.